Profile data is unavailable for this security.
About the company
INIFY Laboratories AB is a Sweden-based medical research company that provides cancer diagnostics through laboratory services within pathology. The Company uses a fully digital, standardized and Artificial Intelligence (AI)- supported workflow to optimize quality and response times, initially within prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. INIFY Laboratories' laboratory in Solna, Sweden is intended to provide two types of analyses of prostate Biopsy Specimens to clients: Full pathology Report signed by an INIFY subspecialized pathologist and Whole Slide Images (WSI) generation and result of Pathology Decision Support Tool (PDST) analysis only. The Company origins from ContextVision.
- Revenue in NOK (TTM)9.58m
- Net income in NOK-52.72m
- Incorporated2021
- Employees26.00
- LocationINIFY Laboratories ABScheeles vag 3SOLNA 171 65SwedenSWE
- Phone+46 8267330
- Websitehttps://www.inify.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vo2 Cap Holding AB (publ) | 353.86m | -56.07m | 128.97m | 94.00 | -- | 0.7048 | -- | 0.3645 | -0.9759 | -0.9759 | 6.46 | 3.16 | 0.7992 | -- | 8.21 | 3,378,952.00 | -12.66 | -0.2564 | -17.29 | -0.3839 | 35.78 | 23.36 | -15.84 | -0.2409 | -- | -6.95 | 0.1429 | -- | -26.09 | 85.65 | -57.92 | -- | -17.96 | -- |
| Toleranzia AB | 0.00 | -7.24m | 136.10m | 11.00 | -- | 0.6564 | -- | -- | -0.0361 | -0.0361 | 0.00 | 0.7526 | 0.00 | -- | -- | 0.00 | -4.31 | -7.45 | -4.56 | -7.78 | -- | -- | -- | -- | -- | -- | 0.0481 | -- | -- | -- | 11.79 | -- | 63.90 | -- |
| Arcoma AB | 174.20m | 13.20m | 141.44m | 32.00 | 10.72 | 2.36 | 6.79 | 0.8119 | 0.9844 | 0.9844 | 12.99 | 4.48 | 1.87 | 3.48 | 7.87 | 5,526,807.00 | 14.18 | 1.12 | 24.21 | 2.01 | 38.29 | 37.66 | 7.58 | 0.7568 | 1.24 | 25.82 | 0.00 | 0.00 | 30.36 | 6.41 | 34.81 | -- | 22.75 | -- |
| Neola Medical AB | 0.00 | -9.63m | 145.50m | 7.00 | -- | 1.94 | -- | -- | -0.1508 | -0.1508 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -12.63 | -17.04 | -13.59 | -18.46 | -- | 4,237.20 | -- | -5,258.78 | -- | -- | 0.00 | -- | -- | -- | 12.97 | -- | 55.46 | -- |
| Nanexa AB | 27.36m | -67.80m | 155.90m | 19.00 | -- | 1.76 | -- | 5.70 | -0.6938 | -0.6938 | 0.2484 | 0.6411 | 0.2108 | -3.83 | 2.99 | 1,416,316.00 | -52.24 | -40.77 | -70.59 | -48.77 | 118.77 | 77.27 | -247.79 | -532.26 | 1.92 | -- | 0.0174 | -- | 925.42 | 147.00 | -30.44 | -- | 39.10 | -- |
| SpectraCure AB (publ) | 2.40m | -21.53m | 158.01m | 13.00 | -- | 1.32 | -- | 65.74 | -0.218 | -0.218 | 0.0243 | 1.21 | 0.0166 | -- | 24.63 | 157,600.00 | -14.82 | -12.75 | -15.91 | -13.62 | 442.39 | 195.30 | -895.85 | -494.40 | -- | -- | 0.0494 | -- | -3.30 | -- | 19.46 | -- | -- | -- |
| Bactiquant A/S | 14.21m | -22.90m | 167.93m | -- | -- | 15.55 | -- | 11.82 | -0.6558 | -0.6558 | 0.4064 | 0.2906 | 0.5101 | 2.94 | 5.06 | -- | -82.23 | -41.26 | -92.65 | -47.16 | -24.34 | 12.89 | -161.20 | -71.77 | 2.73 | -9.48 | 0.5326 | -- | -0.689 | -- | 7.62 | -- | -- | -- |
| Q linea AB | 2.30m | -221.99m | 209.43m | 97.00 | -- | 8.03 | -- | 90.90 | -1.87 | -1.87 | 0.0194 | 0.219 | 0.0107 | 0.1224 | 3.01 | 17,842.52 | -103.05 | -59.66 | -149.74 | -66.14 | -124.10 | -378.58 | -9,635.17 | -4,046.97 | 0.4141 | -- | 0.7825 | -- | -65.28 | 33.02 | 14.64 | -- | 41.94 | -- |
| Micropos Medical AB (publ) | 2.59m | -23.42m | 223.46m | 9.00 | -- | 14.95 | -- | 86.32 | -0.1536 | -0.1536 | 0.017 | 0.0964 | 0.1238 | 0.1034 | 2.09 | 318,247.50 | -112.02 | -64.24 | -154.79 | -82.27 | 82.20 | 114.76 | -904.59 | -767.57 | 2.73 | -- | 0.0249 | -- | 50.23 | 5.94 | -26.57 | -- | -- | -- |
| INIFY Laboratories AB | 9.58m | -52.72m | 244.09m | 26.00 | -- | 5.04 | -- | 25.47 | -1.17 | -1.17 | 0.2119 | 1.07 | 0.1164 | 2.16 | 1.83 | -- | -64.03 | -- | -64.03 | -- | 84.45 | -- | -550.10 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Scandinavian Medical Solutions A/S | 312.29m | 8.49m | 265.25m | 25.00 | 31.07 | 2.17 | 13.85 | 0.8494 | 0.1963 | 0.1963 | 7.22 | 2.81 | 1.38 | 1.89 | 11.35 | -- | 3.75 | -- | 6.15 | -- | 24.48 | -- | 2.72 | -- | 0.4307 | 5.54 | 0.3473 | -- | 72.98 | -- | 7.49 | -- | -- | -- |
| Boule Diagnostics AB | 572.76m | -216.08m | 284.28m | 227.00 | -- | 1.10 | -- | 0.4963 | -5.48 | -5.48 | 14.17 | 6.56 | 0.8515 | 4.58 | 3.95 | 2,470,741.00 | -32.14 | 1.67 | -48.62 | 2.40 | 45.14 | 43.50 | -37.74 | 2.04 | 0.7686 | -24.41 | 0.4116 | 42.24 | 4.24 | 6.13 | 96.24 | -9.45 | -9.74 | -- |
| Karolinska Development AB | 1.93m | -5.74m | 317.70m | 8.00 | -- | 0.256 | -- | 164.20 | -0.0209 | -0.0209 | 0.007 | 4.56 | 0.0015 | -- | 1.38 | 237,875.00 | -0.4536 | 3.37 | -0.4578 | 3.83 | -- | -- | -296.85 | 1,466.36 | -- | -- | 0.0021 | 0.00 | -12.43 | -8.10 | 106.11 | -29.31 | -- | -- |
| Ortoma AB | 48.25m | -30.31m | 333.48m | 7.00 | -- | 1.99 | -- | 6.91 | -0.7638 | -0.7638 | 1.26 | 4.65 | 0.2497 | 1.84 | 8.68 | 6,779,500.00 | -15.68 | -10.45 | -17.11 | -11.64 | 69.05 | 339.86 | -62.81 | -175.52 | 3.39 | -- | 0.00 | -- | -- | -- | -38.87 | -- | 14.14 | -- |
| Acarix AB | 6.36m | -72.13m | 343.93m | 9.00 | -- | 4.56 | -- | 54.06 | -0.1168 | -0.1168 | 0.0095 | 0.0697 | 0.0894 | 0.1172 | 2.47 | -- | -101.38 | -66.93 | -123.43 | -77.12 | 88.27 | 79.42 | -1,133.87 | -1,483.68 | 5.21 | -328.98 | 0.00 | -- | 7.20 | 43.55 | -1.11 | -- | -- | -- |
Data as of Nov 08 2024. Currency figures normalised to INIFY Laboratories AB's reporting currency: Norwegian Krone NOK
8.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Danske Bank A/S (Investment Management Sweden)as of 01 Feb 2024 | 2.05m | 4.53% |
| MP Pensjon PKas of 01 Feb 2024 | 1.37m | 3.03% |
| SEB Investment Management ABas of 01 Feb 2024 | 185.44k | 0.41% |
| Aktia Bank Plc (Investment Management)as of 30 Sep 2024 | 172.70k | 0.38% |
More ▼
Data from 10 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
